EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
15.30
-0.24 (-1.58%)
Jan 21, 2026, 1:46 PM EST - Market open
EyePoint Employees
EyePoint had 165 employees as of December 31, 2024. The number of employees increased by 44 or 36.36% compared to the previous year.
Employees
165
Change (1Y)
44
Growth (1Y)
36.36%
Revenue / Employee
$256,600
Profits / Employee
-$1,246,982
Market Cap
1.27B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 165 | 44 | 36.36% | 165 | 0 |
| Dec 31, 2023 | 121 | -23 | -15.97% | 121 | 0 |
| Dec 31, 2022 | 144 | 21 | 17.07% | 144 | 0 |
| Dec 31, 2021 | 123 | 22 | 21.78% | 122 | 1 |
| Dec 31, 2020 | 101 | 17 | 20.24% | 98 | 3 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EYPT News
- 5 days ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 14 days ago - EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 - GlobeNewsWire
- 5 weeks ago - EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration - GlobeNewsWire
- 2 months ago - EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments - GlobeNewsWire
- 2 months ago - EyePoint Announces Participation at Upcoming Investor Conferences - GlobeNewsWire